Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049919 · ClinicalTrials.gov registry record · NA
Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)
A NA study, sponsored by Zimmer Biomet.
- Terminated
- Registry status
- NA
- Development phase
- 153
- Enrollment target
NCT01049919 is a NA study that was terminated before completion, run by Zimmer Biomet. The registered enrollment target is 153 participants.
The verdict
NCT01049919, a NA study, was terminated before completion, sponsored by Zimmer Biomet.
- TERMINATED
- Registry status
- NA
- Development phase
- 153 participants
- Enrollment target
Study Summary
This trial will evaluate the safety and efficacy of concentrated bone marrow aspirate (cBMA) to prevent or delay major amputation and/or death in subjects with critical limb ischemia (CLI) due to severe peripheral arterial disease (PAD).
Interventions
- DEVICE Bone marrow concentration device
- PROCEDURE Placebo procedure (sham)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2010-06 |
| Est. Completion | 2020-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01049919
The ClinicalTrials.gov registry entry for NCT01049919 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zimmer Biomet, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bone marrow concentration device is the first listed.
NCT01049919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01049919 about?
NCT01049919 is a clinical study titled "Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)". This trial will evaluate the safety and efficacy of concentrated bone marrow aspirate (cBMA) to prevent or delay major amputation and/or death in subjects with critical limb ischemia (CLI) due to severe peripheral arterial disease (PAD).
What is the current status of trial NCT01049919?
This trial is currently terminated. It is a NA study. The enrollment target is 153 participants. The study started on 2010-06. Estimated completion is 2020-02.
What interventions are being tested in trial NCT01049919?
The interventions under investigation include: Bone marrow concentration device (DEVICE), Placebo procedure (sham) (PROCEDURE).
Who is sponsoring clinical trial NCT01049919?
This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.